Synaptogenix Welcomes Lecanemab Phase 3 Trial Results ...Middle East

PR Newswire - News
Synaptogenix expecting data from its Phase 2 clinical trial of Bryostatin-1 for advanced Alzheimer's disease in fourth quarter 2022 NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company...

Read More Details
Finally We wish PressBee provided you with enough information of ( Synaptogenix Welcomes Lecanemab Phase 3 Trial Results )

Apple Storegoogle play

Also on site :



Latest News